Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
UBS
Medtronic
QuintilesIMS
Fish and Richardson
Farmers Insurance
Covington
Merck
Dow

Generated: June 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,528,091

« Back to Dashboard

Which drugs does patent 6,528,091 protect, and when does it expire?

Patent 6,528,091 protects DEPAKOTE ER and is included in one NDA.

Protection for DEPAKOTE ER has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in twenty-seven countries.
Summary for Patent: 6,528,091
Title: Controlled release formulation of divalproex sodium
Abstract:A controlled release tablet formulation which permits once daily dosing in the treatment of epilepsy comprises from about 50 weight percent to about 55 weight percent of an active ingredient selected from the group consisting of valproic acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, and valpromide; from about 20 weight percent to about 40 weight percent hydroxypropyl methylcellulose; from about 5 weight percent to about 15 weight percent lactose, from about 4 weight percent to about 6 weight percent microcrystalline cellulose, and from about 1 weight percent to about 5 weight percent silicon dioxide having an average particle size ranging between about 1 micron and about 10 microns; all weight percentages based upon the total weight of the tablet dosage form. Also disclosed are pre-tableting granular formulations, methods of making the granular formulations and tablets, and a method of treating epilepsy employing the controlled release tablet formulations of the invention.
Inventor(s): Qiu; Yihong (Gurnee, IL), Poska; Paul Richard (Mundelein, IL), Cheskin; Howard S. (Glencoe, IL), Bollinger; J. Daniel (Libertyville, IL), Engh; Robert K. (Kenosha, WI)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/143,559
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,528,091
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 6,528,091

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,528,091

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,419,953 Controlled release formulation of divalproex sodium ➤ Sign Up
6,528,090 Controlled release formulation of divalproex sodium ➤ Sign Up
6,511,678 Controlled release formulation of divalproex sodium ➤ Sign Up
6,720,004 Controlled release formulation of divalproex sodium ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fish and Richardson
Cipla
QuintilesIMS
Accenture
Deloitte
Citi
McKinsey
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.